Detecting melanoma early leads to a nearly 100% cure rate, but diagnosing it at an advanced stage results in less than 20% survival. The power of early diagnosis has made it the major approach to preventing death from melanoma. Yet there is little evidence that large public skin cancer screenings prevent melanoma deaths. Focusing on people at greatest risk would be possible with an early predictor of risk that helps the primary care physician identify patients who should be followed by a dermatologist. This preventive test needs to measure both aspects of melanoma risk: genetic risk and sun-exposure risk. Project 1 focuses on sun-exposure risk because most people with Fitzpatrick Type I skin do not get melanoma. Yet UV exposure is usually ascertained by patient recollections rather than by objective biological indicators of past sun exposure. To overcome this critical barrier to assessing personal UV exposure and thus melanoma risk, we propose to couple two new technologies with Next-Gen sequencing to create genomic surrogate biomarkers of long-term sun exposure. One dosimeter takes advantage of the accumulation of DNA photoproducts in special regions of the genome;the other incorporates our knowledge about clonal expansion of cells in skin. We then evaluate these genomic dosimeter readings in skin for association with melanoma.
The Specific Aims are:
Aim 1 : Map human genomic regions that are UV damage hotspots or DNA repair slowspots.
Aim 2 : Quantitate rare UV-mutated genes in skin in vivo.
Aim 3 : Use genomic regions sensitive to UV photoproducts and mutations as dosimeters to correlate cumulative sunlight exposure in normal skin to risk for melanoma. These studies establish ways to objectively ascertain exposure to cancer risk using modern measurement technologies.

Public Health Relevance

A simple test that allows a primary care physician to identify individuals at risk for melanoma, and so refer them to a dermatologist for surveillance, would increase early diagnosis and survival, reduce screening costs, and probably prevent melanomas by altering behavior. A critical barrier is an objective test for a patient's cumulative sun exposure. This project will develop genome-based dosimeters for cumulative sun exposure and then tests them in a pilot association study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121974-08
Application #
8719043
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
City
New Haven
State
CT
Country
United States
Zip Code
06510
Brash, Douglas E (2016) UV-induced Melanin Chemiexcitation: A New Mode of Melanoma Pathogenesis. Toxicol Pathol 44:552-4
Premi, Sanjay; Brash, Douglas E (2016) Chemical excitation of electrons: A dark path to melanoma. DNA Repair (Amst) 44:169-77
Jiang, Yu; Shi, Xingjie; Zhao, Qing et al. (2016) Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. Genomics 107:223-30
Cyrus, Nika; Mai-Anh Bui, Christine; Yao, Xiaopan et al. (2016) Density and Polarization States of Tumor-Associated Macrophages in Human Cutaneous Squamous Cell Carcinomas Arising in Solid Organ Transplant Recipients. Dermatol Surg 42 Suppl 1:S18-23
Robles-Espinoza, Carla Daniela; Roberts, Nicola D; Chen, Shuyang et al. (2016) Germline MC1R status influences somatic mutation burden in melanoma. Nat Commun 7:12064
Gibson, Juliet F; Huang, Jing; Liu, Kristina J et al. (2016) Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction. J Am Acad Dermatol 74:870-7
Wang, Xuefeng; Chen, Mengjie; Yu, Xiaoqing et al. (2016) Global copy number profiling of cancer genomes. Bioinformatics 32:926-8
Wang, Yu; Zhao, Yinjun; Ma, Shuangge (2016) Racial differences in six major subtypes of melanoma: descriptive epidemiology. BMC Cancer 16:691
Weed, Jason; Gibson, Juliet; Lewis, Julia et al. (2016) FISH Panel for Leukemic CTCL. J Invest Dermatol :
Halaban, Ruth; Krauthammer, Michael (2016) RASopathy Gene Mutations in Melanoma. J Invest Dermatol 136:1755-9

Showing the most recent 10 out of 134 publications